Source comparison
PT-141 Melanotan-2 Stack Tanning and Libido Protocol 2026: Comparison
Primary Receptor Target MC4R (hypothalamic) MC1R, MC3R, MC4R, MC5R (broad-spectrum) MC4R + MC1R simultaneously Non-competing pathways allow concurrent use without receptor saturation Typical Research Dose 1–2mg subcutaneous 250–500mcg subcutaneous Staggered: M
This comparison does not assign a generated winner or score.
- Primary Receptor Target
- MC4R (hypothalamic)
- MC1R, MC3R, MC4R, MC5R (broad-spectrum)
- MC4R + MC1R simultaneously
- Non-competing pathways allow concurrent use without receptor saturation
- Typical Research Dose
- 1–2mg subcutaneous
- 250–500mcg subcutaneous
- Staggered: MT-2 first, PT-141 24–48h later
- Lower doses than monotherapy due to additive melanocortin effects
- Plasma Half-Life
- ~2.7 hours
- ~0.55 hours (33 minutes)
- N/A. Independent kinetics
- Short half-lives require precise timing for desired effect windows
- Receptor Occupancy Duration
- 4–6 hours at MC4R
- 24–48 hours at MC1R
- Overlapping but offset windows
- Staggered dosing prevents simultaneous peak plasma concentrations
- Reconstituted Stability
- 28 days at 2–8°C
- 30 days at 2–8°C
- Both require identical cold-chain storage
- Temperature excursion >8°C denatures both peptides irreversibly
- Primary Research Application
- Libido/arousal pathways
- Melanogenesis/photoprotection
- Dual melanocortin pathway activation
- Stack addresses two distinct biological endpoints without redundancy